Alfuzosin, a selective α1‐adrenoceptor antagonist in the lower urinary tract
Open Access
- 1 August 1993
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 109 (4) , 1282-1289
- https://doi.org/10.1111/j.1476-5381.1993.tb13762.x
Abstract
1 Phenylephrine-induced contractions of rabbit isolated trigone and urethra were antagonized in a competitive manner by alfuzosin (pA2 7.44 and 7.30, respectively) and prazosin. 2 The characteristics of [3H]-prazosin binding to human prostatic adenoma tissue were evaluated. [3H]-prazosin was potently displaced by α1-adrenoceptor specific agents including alfuzosin, its (+)- and (−)-enantiomers and prazosin (IC50 0.035, 0.023, 0.019 and 0.004 μm, respectively), but only weakly by α2-adrenoceptor selective agents, for example, yohimbine (IC50 = 6.0 μm). 3 In the pithed rat, alfuzosin (0.03–0.3 mg kg−1, i.v.) markedly inhibited pressor responses produced by the α1-selective agonist, cirazoline but inhibited only slightly responses to the α2-selective agonist, UK 14,304. Alfuzosin (1 mg kg−1, i.v.) had minimal effects against responses mediated by stimulation of prejunctional α2-receptors (UK 14,304-induced inhibition of sympathetic tachycardia). 4 In the anaesthetized cat, alfuzosin (0.001–1 mg kg−1, i.v.) and prazosin (0.001–0.3 mg kg−1, i.v.) produced dose-related inhibition of the increases in urethral pressure caused by stimulation of sympathetic hypogastric nerves. Prazosin was approximately 5 fold more potent than alfuzosin. When phenylephrine was employed to induce urethral and vascular α1-mediated tone simultaneously, prazosin inhibited both stimuli with similar potency whereas alfusozin was 3–5 fold more potent against elevated urethral pressure. This functional uroselectivity of alfuzosin was more evident by the intraduodenal route, since doses of 0.03 and 0.1 mg kg−1 alfuzosin inhibited urethral pressure with minimal effects on arterial blood pressure. 5 Alfuzosin is a potent selective α1-adrenoceptor antagonist in tissues of the lower urinary tract including the human prostate. This provides a pharmacological basis for its use in the treatment of benign prostatic hypertrophy.Keywords
This publication has 20 references indexed in Scilit:
- Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5.Published by Elsevier ,2021
- Alfuzosin for treatment of benign prostatic hypertrophyThe Lancet, 1991
- Alpha-adrenoceptor blockers in the treatment of benign prostatic hyperplasiaWorld Journal of Urology, 1991
- In vitro and in vivo studies on the effects of the alpha‐adrenoceptor blocker IP/66 (1‐(2‐ethoxy‐2‐(3′ ‐pyridyl)ethyl)‐4‐(2′‐methoxy‐phenyl)piperazine) on urethral tone in ratsDrug Development Research, 1991
- In vitro characterization of the α-adrenoceptors in human prostateEuropean Journal of Pharmacology, 1985
- The contractions induced in rat and guinea-pig aortic strips by the α2-adrenoceptor selective agonists B-HT 920 and UK 14,304 are mediated by α1-adrenoceptorsEuropean Journal of Pharmacology, 1984
- α1- and α2-adrenoceptors in the smooth muscle of isolated rabbit urinary bladder and urethraEuropean Journal of Pharmacology, 1984
- Ryanodine prolongs Ca‐currents while suppressing contraction in rat ventricular muscle cellsBritish Journal of Pharmacology, 1984
- Presence of Postsynaptic α2-Adrenoreceptors of Predominantly Extrasynaptic Location in the Vascular Smooth Muscle of the Dog Hind LimbClinical Science, 1980
- Presynaptic regulation of catecholamine releaseBiochemical Pharmacology, 1974